Candel Therapeutics (CADL) Gains from Investment Securities (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Gains from Investment Securities data on file, last reported at $13.5 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities rose 131.81% year-over-year to $13.5 million; the trailing twelve-month figure through Dec 2025 stood at -$8.2 million (down 139.41% YoY), and the FY2025 full-year result was -$8.2 million, down 139.41% from the prior year.
• Gains from Investment Securities grew to $13.5 million in Q4 2025, from -$1.1 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.5 million in Q4 2025 to a low of -$14.9 million in Q1 2025.
• A 5-year average of $352052.6 and a median of -$369000.0 in 2022 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities jumped 9363.19% in 2024 and slumped 212485.71% in 2025, its largest moves.
• Tracing CADL's Gains from Investment Securities over 5 years: stood at -$9.2 million in 2021, then jumped by 70.17% to -$2.7 million in 2022, then surged by 117.6% to $483000.0 in 2023, then surged by 1107.45% to $5.8 million in 2024, then soared by 131.81% to $13.5 million in 2025.
• Business Quant data shows CADL's Gains from Investment Securities at $13.5 million in Q4 2025, -$1.1 million in Q3 2025, and -$5.7 million in Q2 2025.